Published in Virology on March 30, 2003
Quasispecies theory and the behavior of RNA viruses. PLoS Pathog (2010) 3.19
Viral quasispecies evolution. Microbiol Mol Biol Rev (2012) 2.69
Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol (2006) 2.61
The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol (2005) 1.91
Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest. Proc Natl Acad Sci U S A (2009) 1.72
Replicon system for Lassa virus. J Virol (2004) 1.69
Suppression of viral infectivity through lethal defection. Proc Natl Acad Sci U S A (2005) 1.62
Mutagenesis versus inhibition in the efficiency of extinction of foot-and-mouth disease virus. J Virol (2003) 1.58
Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J Virol (2006) 1.56
The role of mutational robustness in RNA virus evolution. Nat Rev Microbiol (2013) 1.54
Fidelity variants of RNA dependent RNA polymerases uncover an indirect, mutagenic activity of amiloride compounds. PLoS Pathog (2010) 1.34
Coxsackievirus B3 mutator strains are attenuated in vivo. Proc Natl Acad Sci U S A (2012) 1.32
Preextinction viral RNA can interfere with infectivity. J Virol (2004) 1.26
Exploiting drug repositioning for discovery of a novel HIV combination therapy. J Virol (2010) 1.17
Lethal mutagenesis of poliovirus mediated by a mutagenic pyrimidine analogue. J Virol (2007) 1.16
Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J Virol (2007) 1.10
A multi-step process of viral adaptation to a mutagenic nucleoside analogue by modulation of transition types leads to extinction-escape. PLoS Pathog (2010) 1.08
Targeting the proteolytic processing of the viral glycoprotein precursor is a promising novel antiviral strategy against arenaviruses. J Virol (2010) 1.06
Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections. PLoS Pathog (2009) 1.05
Lethal mutagenesis: targeting the mutator phenotype in cancer. Semin Cancer Biol (2010) 1.05
Ribavirin can be mutagenic for arenaviruses. J Virol (2011) 1.03
Use of single-cycle infectious lymphocytic choriomeningitis virus to study hemorrhagic fever arenaviruses. J Virol (2010) 1.03
Adaptation and immunity. PLoS Biol (2004) 1.01
Examining the theory of error catastrophe. J Virol (2006) 1.00
Therapeutically targeting RNA viruses via lethal mutagenesis. Future Virol (2008) 0.99
Arenavirus variations due to host-specific adaptation. Viruses (2013) 0.99
HLA-A2-restricted protection against lethal lymphocytic choriomeningitis. J Virol (2006) 0.99
Mutagenesis-induced, large fitness variations with an invariant arenavirus consensus genomic nucleotide sequence. J Virol (2005) 0.98
Genetic and phenotypic variation of foot-and-mouth disease virus during serial passages in a natural host. J Virol (2007) 0.97
Isolation of fidelity variants of RNA viruses and characterization of virus mutation frequency. J Vis Exp (2011) 0.97
Characterization of Lassa virus cell entry and neutralization with Lassa virus pseudoparticles. J Virol (2009) 0.97
Inhibition of chikungunya virus replication by harringtonine, a novel antiviral that suppresses viral protein expression. Antimicrob Agents Chemother (2012) 0.95
Anti-HIV-1 activity of resveratrol derivatives and synergistic inhibition of HIV-1 by the combination of resveratrol and decitabine. Bioorg Med Chem Lett (2012) 0.94
Back to the future: revisiting HIV-1 lethal mutagenesis. Trends Microbiol (2012) 0.90
Progress in the experimental therapy of severe arenaviral infections. Future Microbiol (2011) 0.90
Evaluation of the anti-arenaviral activity of the subtilisin kexin isozyme-1/site-1 protease inhibitor PF-429242. Virology (2011) 0.89
Ribavirin-resistant variants of foot-and-mouth disease virus: the effect of restricted quasispecies diversity on viral virulence. J Virol (2014) 0.86
Novel approaches in anti-arenaviral drug development. Virology (2010) 0.86
5,6-Dihydro-5-aza-2'-deoxycytidine potentiates the anti-HIV-1 activity of ribonucleotide reductase inhibitors. Bioorg Med Chem (2013) 0.85
Reverse genetics approaches to combat pathogenic arenaviruses. Antiviral Res (2008) 0.85
Does mutational robustness inhibit extinction by lethal mutagenesis in viral populations? PLoS Comput Biol (2010) 0.83
Tempo and mode of inhibitor-mutagen antiviral therapies: a multidisciplinary approach. Proc Natl Acad Sci U S A (2011) 0.83
Effective lethal mutagenesis of influenza virus by three nucleoside analogs. J Virol (2015) 0.83
Lethal mutagenesis in a structured environment. J Theor Biol (2009) 0.82
Deciphering Evolutionary Mechanisms Between Mutualistic and Pathogenic Symbioses. Vie Milieu Paris (2008) 0.82
Host cell factors as antiviral targets in arenavirus infection. Viruses (2012) 0.81
Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis. PLoS One (2013) 0.81
On the possible role of robustness in the evolution of infectious diseases. Chaos (2010) 0.81
Mutagenesis-mediated virus extinction: virus-dependent effect of viral load on sensitivity to lethal defection. PLoS One (2012) 0.80
Arenaviruses and lethal mutagenesis. Prospects for new ribavirin-based interventions. Viruses (2012) 0.79
Template properties of mutagenic cytosine analogues in reverse transcription. Nucleic Acids Res (2006) 0.77
Reverse Genetics Approaches to Control Arenavirus. Methods Mol Biol (2016) 0.75
Reporter-Expressing, Replicating-Competent Recombinant Arenaviruses. Viruses (2016) 0.75
Changes in protein domains outside the catalytic site of the bacteriophage Qβ replicase reduce the mutagenic effect of 5-azacytidine. J Virol (2014) 0.75
Biological and biomedical implications of the co-evolution of pathogens and their hosts. Nat Genet (2002) 4.42
Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science (2013) 4.18
Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol (2006) 2.61
Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection. Nat Med (2004) 2.59
Structure of foot-and-mouth disease virus RNA-dependent RNA polymerase and its complex with a template-primer RNA. J Biol Chem (2004) 2.48
Identification of the lymphocytic choriomeningitis virus (LCMV) proteins required to rescue LCMV RNA analogs into LCMV-like particles. J Virol (2002) 1.97
Differential inhibition of type I interferon induction by arenavirus nucleoproteins. J Virol (2007) 1.95
Ube1L and protein ISGylation are not essential for alpha/beta interferon signaling. Mol Cell Biol (2006) 1.80
Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA. Proc Natl Acad Sci U S A (2006) 1.79
Role of the virus nucleoprotein in the regulation of lymphocytic choriomeningitis virus transcription and RNA replication. J Virol (2003) 1.69
Suppression of viral infectivity through lethal defection. Proc Natl Acad Sci U S A (2005) 1.62
Evolutionary transition toward defective RNAs that are infectious by complementation. J Virol (2004) 1.61
Selective inhibitor of endosomal trafficking pathways exploited by multiple toxins and viruses. Proc Natl Acad Sci U S A (2013) 1.60
Mutagenesis versus inhibition in the efficiency of extinction of foot-and-mouth disease virus. J Virol (2003) 1.58
Myristoylation of the RING finger Z protein is essential for arenavirus budding. J Virol (2004) 1.58
Effect of alternating passage on adaptation of sindbis virus to vertebrate and invertebrate cells. J Virol (2005) 1.57
Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J Virol (2006) 1.56
Characterization of the genomic promoter of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol (2003) 1.56
The structure of a protein primer-polymerase complex in the initiation of genome replication. EMBO J (2006) 1.54
Crystal structure of the Lassa virus nucleoprotein-RNA complex reveals a gating mechanism for RNA binding. Proc Natl Acad Sci U S A (2011) 1.51
Characterization of the arenavirus RING finger Z protein regions required for Z-mediated inhibition of viral RNA synthesis. J Virol (2002) 1.44
Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. Virology (2003) 1.44
Recombinant lymphocytic choriomeningitis virus expressing vesicular stomatitis virus glycoprotein. Proc Natl Acad Sci U S A (2003) 1.41
Kinetics of protective antibodies are determined by the viral surface antigen. J Clin Invest (2004) 1.39
Sequential structures provide insights into the fidelity of RNA replication. Proc Natl Acad Sci U S A (2007) 1.37
Dual role of the lymphocytic choriomeningitis virus intergenic region in transcription termination and virus propagation. J Virol (2005) 1.36
High mutation rates, bottlenecks, and robustness of RNA viral quasispecies. Gene (2005) 1.31
Resistance of virus to extinction on bottleneck passages: study of a decaying and fluctuating pattern of fitness loss. Proc Natl Acad Sci U S A (2003) 1.27
Preextinction viral RNA can interfere with infectivity. J Virol (2004) 1.26
The Ebola virus glycoprotein mediates entry via a non-classical dynamin-dependent macropinocytic pathway. Virology (2011) 1.22
Structural insights into replication initiation and elongation processes by the FMDV RNA-dependent RNA polymerase. Curr Opin Struct Biol (2009) 1.22
Duration and fitness dependence of quasispecies memory. J Mol Biol (2002) 1.18
Insights into RNA virus mutant spectrum and lethal mutagenesis events: replicative interference and complementation by multiple point mutants. J Mol Biol (2007) 1.17
A reverse genetics system for Borna disease virus. J Gen Virol (2003) 1.16
Arenavirus nucleoprotein targets interferon regulatory factor-activating kinase IKKε. J Virol (2012) 1.15
Mutant viral polymerase in the transition of virus to error catastrophe identifies a critical site for RNA binding. J Mol Biol (2005) 1.13
Inhibition of the type I interferon antiviral response during arenavirus infection. Viruses (2010) 1.11
The z protein of the new world arenavirus tacaribe virus has bona fide budding activity that does not depend on known late domain motifs. J Virol (2009) 1.10
Evidence for quasispecies distributions in the human hepatitis A virus genome. Virology (2003) 1.10
Mapping the landscape of the lymphocytic choriomeningitis virus stable signal peptide reveals novel functional domains. J Virol (2007) 1.09
A multi-step process of viral adaptation to a mutagenic nucleoside analogue by modulation of transition types leads to extinction-escape. PLoS Pathog (2010) 1.08
Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome. PLoS One (2012) 1.06
Antiviral activity of a small-molecule inhibitor of arenavirus glycoprotein processing by the cellular site 1 protease. J Virol (2010) 1.06
Hidden virulence determinants in a viral quasispecies in vivo. J Virol (2008) 1.06
Junín virus infection activates the type I interferon pathway in a RIG-I-dependent manner. PLoS Negl Trop Dis (2012) 1.05
Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections. PLoS Pathog (2009) 1.05
Molecular basis for a lack of correlation between viral fitness and cell killing capacity. PLoS Pathog (2007) 1.04
Ribavirin can be mutagenic for arenaviruses. J Virol (2011) 1.03
Viral genome segmentation can result from a trade-off between genetic content and particle stability. PLoS Genet (2011) 1.03
Arenavirus genetic diversity and its biological implications. Infect Genet Evol (2009) 1.03
Initial fitness recovery of HIV-1 is associated with quasispecies heterogeneity and can occur without modifications in the consensus sequence. PLoS One (2010) 1.02
Competition-colonization dynamics in an RNA virus. Proc Natl Acad Sci U S A (2010) 1.01
No evidence of selection for mutational robustness during lethal mutagenesis of lymphocytic choriomeningitis virus. Virology (2008) 1.01
Structure of foot-and-mouth disease virus mutant polymerases with reduced sensitivity to ribavirin. J Virol (2010) 1.01
Past, present, and future of arenavirus taxonomy. Arch Virol (2015) 1.00
Dynamics of mutation and recombination in a replicating population of complementing, defective viral genomes. J Mol Biol (2006) 1.00
Identification of MAVS splicing variants that interfere with RIGI/MAVS pathway signaling. Mol Immunol (2008) 0.99
Resistance to extinction of low fitness virus subjected to plaque-to-plaque transfers: diversification by mutation clustering. J Mol Biol (2002) 0.98
Cells expressing the RING finger Z protein are resistant to arenavirus infection. J Virol (2004) 0.98
Quasispecies as a matter of fact: viruses and beyond. Virus Res (2011) 0.98
Mutagenesis-induced, large fitness variations with an invariant arenavirus consensus genomic nucleotide sequence. J Virol (2005) 0.98
Expansion of host-cell tropism of foot-and-mouth disease virus despite replication in a constant environment. J Gen Virol (2004) 0.97
RNA interference-mediated virus clearance from cells both acutely and chronically infected with the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol (2005) 0.97
A cell-based luciferase assay amenable to high-throughput screening of inhibitors of arenavirus budding. Virology (2008) 0.97
Pathways to extinction: beyond the error threshold. Philos Trans R Soc Lond B Biol Sci (2010) 0.97
Multidrug-resistant HIV-1 reverse transcriptase: involvement of ribonucleotide-dependent phosphorolysis in cross-resistance to nucleoside analogue inhibitors. J Mol Biol (2002) 0.96
Altered central nervous system gene expression caused by congenitally acquired persistent infection with lymphocytic choriomeningitis virus. J Virol (2006) 0.96
Counteracting quasispecies adaptability: extinction of a ribavirin-resistant virus mutant by an alternative mutagenic treatment. PLoS One (2009) 0.94
Guinea pig-adapted foot-and-mouth disease virus with altered receptor recognition can productively infect a natural host. J Virol (2007) 0.93
Hypomorphic mutation in the site-1 protease Mbtps1 endows resistance to persistent viral infection in a cell-specific manner. Cell Host Microbe (2011) 0.93
Beneficial effects of population bottlenecks in an RNA virus evolving at increased error rate. J Mol Biol (2008) 0.93
Role of the host cell's unfolded protein response in arenavirus infection. J Virol (2010) 0.93
Adaptability costs in immune escape variants of vesicular stomatitis virus. Virus Res (2005) 0.92
Minority report: hidden memory genomes in HIV-1 quasispecies and possible clinical implications. AIDS Rev (2008) 0.92
Evolution of cell recognition by viruses: a source of biological novelty with medical implications. Adv Virus Res (2003) 0.92
Mutation hot spots in hepatitis B surface antigen in chronic carriers from Khoozestan province, southern of Iran. Iran J Allergy Asthma Immunol (2013) 0.92
Lethal mutagenesis of viruses. Curr Opin Virol (2011) 0.92
Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection. Virology (2005) 0.92
The impact of quasispecies dynamics on the use of therapeutics. Trends Microbiol (2012) 0.91
Identification of the Borna disease virus (BDV) proteins required for the formation of BDV-like particles. J Gen Virol (2005) 0.91
Envelope exchange for the generation of live-attenuated arenavirus vaccines. PLoS Pathog (2006) 0.91
Fitness increase of memory genomes in a viral quasispecies. J Mol Biol (2004) 0.91
Evidence of the coevolution of antigenicity and host cell tropism of foot-and-mouth disease virus in vivo. J Virol (2003) 0.90
Repeated bottleneck transfers can lead to non-cytocidal forms of a cytopathic virus: implications for viral extinction. J Mol Biol (2007) 0.90
Modeling viral genome fitness evolution associated with serial bottleneck events: evidence of stationary states of fitness. J Virol (2002) 0.90
Invariant aphthovirus consensus nucleotide sequence in the transition to error catastrophe. Infect Genet Evol (2005) 0.90
A methionine-rich domain mediates CRM1-dependent nuclear export activity of Borna disease virus phosphoprotein. J Virol (2006) 0.89
Evaluation of the anti-arenaviral activity of the subtilisin kexin isozyme-1/site-1 protease inhibitor PF-429242. Virology (2011) 0.89
Molecular characterization of a dual inhibitory and mutagenic activity of 5-fluorouridine triphosphate on viral RNA synthesis. Implications for lethal mutagenesis. J Mol Biol (2008) 0.89
A segmented form of foot-and-mouth disease virus interferes with standard virus: a link between interference and competitive fitness. Virology (2005) 0.88
Topology of evolving, mutagenized viral populations: quasispecies expansion, compression, and operation of negative selection. BMC Evol Biol (2008) 0.88
Conserved residues in Lassa fever virus Z protein modulate viral infectivity at the level of the ribonucleoprotein. J Virol (2011) 0.88
Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype. J Virol (2013) 0.88
Synchronous loss of quasispecies memory in parallel viral lineages: a deterministic feature of viral quasispecies. J Mol Biol (2003) 0.88
Fitness distributions in exponentially growing asexual populations. Phys Rev Lett (2003) 0.87